TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

TriLink BioTechnologies® and Lonza Establish Non-Exclusive Agreement for CleanCap® mRNA Capping Technology

Wednesday, May 01, 2024

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences and a leader in life science reagents and services, has recently collaborated with Lonza, a key player in the pharmaceutical, biotech, and nutrition sectors, through a non-exclusive License and Supply Agreement. This partnership aims to broaden access to TriLink's CleanCap® mRNA capping technologies in response to the growing demand for mRNA-based therapies.

As per the agreement, TriLink will provide Lonza with its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for integration into Lonza's global mRNA development and manufacturing services, spanning from pre-clinical stages to Phase III trials. CleanCap® technology, boasting an efficiency of over 95%, simplifies mRNA production processes significantly compared to traditional methods.

Drew Burch, President of Nucleic Acid Production at TriLink, expressed excitement about the collaboration, emphasizing how CleanCap® technology expedites the transition of programs from discovery to clinical trials by improving mRNA function, streamlining manufacturing, and optimizing capped material yield. This partnership further solidifies TriLink's position as a key player in advancing the mRNA capping industry.

TriLink's CleanCap® capping technology, introduced in 2017, has become integral to the production of approved mRNA and saRNA vaccines. Notably, the introduction of CleanCap® M6 in May 2023 marked a significant milestone, with studies indicating a notable increase in mRNA expression compared to enzymatic capping methods.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit